Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Insiders Buying KalVista Pharmaceuticals And 3 Other Stocks

Published 11/01/2024, 11:40
Updated 11/01/2024, 13:10
© Reuters.  Insiders Buying KalVista Pharmaceuticals And 3 Other Stocks
CDMO
-
STAA
-
KALV
-
SCWX
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

STAAR Surgical

  • The Trade: STAAR Surgical Company (NASDAQ: STAA) 10% owner Neal Bradsher acquired a total of 4,042 shares an average price of $27.11. To acquire these shares, it cost around $109,570.
  • What’s Happening: STAAR Surgical issued preliminary fourth-quarter and FY23 net sales guidance above estimates.
  • What STAAR Surgical Does: Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye.
KalVista Pharmaceuticals
  • The Trade: KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) 10% owner Nimish Shah acquired a total of 137,700 shares at an average price of $12.54. To acquire these shares, it cost around $1.73 million. The company’s Chief Scientific Officer also sold 17,321 shares of the company.
  • What’s Happening: KalVista Pharma, last month, announced publication of first oral factor XIIa data in Frontiers in Pharmacology.
  • What KalVista Pharmaceuticals Does: KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Avid Bioservices

  • The Trade: Avid Bioservices, Inc. (NASDAQ: CDMO) Director Richard B Hancock bought a total of 38,803 shares at an average price of $5.21. To acquire these shares, it cost around $202,036.
  • What’s Happening: Avid Bioservices, last month, reported worse-than-expected second-quarter financial results and lowered FY24 revenue guidance below estimates.
  • What Avid Bioservices Does: Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture.
SecureWorks
  • The Trade: SecureWorks Corp. (NASDAQ: SCWX) 10% owner Neil Gagnon bought a total of 11,694 shares at an average price of $6.40. The insider spent around $74,816 to buy those shares.
  • What’s Happening: SecureWorks, last month, reported better-than-expected third-quarter sales.
  • What SecureWorks Does: SecureWorks Corp is a cybersecurity provider of technology-driven solutions singularly focused on protecting its customers by outpacing and outmaneuvering the adversary.

Check This Out: How To Earn $500 A Month From JPMorgan Stock Ahead Of Q4 Earnings Report

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.